Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
The Affiliated People's Hospital of Ningbo University